✦ LIBER ✦

Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer: A hoosier oncology group study

✍ Scribed by Scott Saxman; Rafat Ansari; Ray Drasga; Michael Miller; Ben Wheeler; John McClean; Lawrence Einhorn

Publisher: John Wiley and Sons
Year: 1992
Tongue: English
Weight: 489 KB
Volume: 70
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19921115)70:10<2488::aid-cncr2820701016>3.0.co;2-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Methotrexate, vinblastine, doxorubicin,

Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the hoosier oncology group

✍ Bruce J. Roth; George W. Sledge Jr; Stephen D. Williams; Steven C. Meyer; Rafat 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 490 KB 👁 1 views

Forty-six eligible patients with metastatic breast cancer (MBC) were treated with a combination of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) as first-line chemotherapy. Of 44 patients evaluable for response, 28 (64%) had an objective response, including seven (16%) who had a comp

Cyclophosphamide, methotrexate, and 5-fl

Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A southwest oncology group study

✍ Antoinette J. Wozniak; Brent A. Blumenstein; E. David Crawford; Michael Boileau; 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 381 KB 👁 2 views

A phase II trial of estramustine and eto

A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407)

✍ Kenneth J. Pienta; Emily I. Fisher; Mario A. Eisenberger; Glenn M. Mills; J. Wen 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 1 views

BACKGROUND. The combination of oral estramustine and oral etoposide has generated response rates of 40±50% in patients with hormone refractory prostate cancer in single institution trials. This study tested this regimen in a multi-institutional setting. METHODS. Fifty-®ve patients were accrued over